Expand LGVN Menu
LGVN MENU

LGVN Latest Press Releases

-- June 18, 2026 --

New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) Globe Newswire 9:20 AM

-- June 9, 2026 --

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA) Globe Newswire 9:20 AM

-- June 4, 2026 --

Longeveron to Present at BIO International Convention 2026 Globe Newswire 9:15 AM

-- May 20, 2026 --

Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities Globe Newswire 4:05 PM

-- May 13, 2026 --

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- May 11, 2026 --

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS) Globe Newswire 9:10 AM

-- May 8, 2026 --

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) Globe Newswire 4:05 PM

-- May 5, 2026 --

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026 Globe Newswire 4:15 PM

-- April 23, 2026 --

The Longevity Trade Is No Longer a Buzzword - It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial Globe Newswire 6:15 AM

-- April 8, 2026 --

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) Globe Newswire 9:15 AM

-- March 18, 2026 --

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed Globe Newswire 11:30 AM

-- March 17, 2026 --

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- March 12, 2026 --

Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 Globe Newswire 9:00 AM

-- March 11, 2026 --

Longeveron Announces Closing of Private Placement of up to $30 Million Globe Newswire 4:05 PM

-- March 10, 2026 --

Longeveron Announces Private Placement of up to $30 Million Globe Newswire 9:00 AM

-- February 25, 2026 --

Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell Globe Newswire 11:05 AM

-- February 13, 2026 --

Longeveron Appoints Stephen H. Willard as Chief Executive Officer Globe Newswire 4:30 PM

-- February 5, 2026 --

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program Globe Newswire 9:15 AM

-- January 29, 2026 --

Longeveron Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) Globe Newswire 9:15 AM

-- January 26, 2026 --

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) Globe Newswire 9:15 AM
Market Data Delayed 15 Minutes